Genmab A/S

GMAB

Equity

ISIN null / Valor 21487099

NASDAQ (2026-07-02)

USD 28.52+3.17%

Genmab A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Genmab A/S is a Copenhagen‑based biotechnology company that discovers and develops antibody therapeutics, with a particular focus on oncology. The company uses proprietary platforms such as DuoBody (bispecific antibodies) and HexaBody (Fc‑engineered antibodies) to generate differentiated monoclonal and multispecific candidates and advances a pipeline of programs through preclinical and clinical stages. Genmab’s business model combines in‑house research with partnering agreements with larger pharmaceutical companies for late‑stage development and commercialization, generating revenue from milestone payments, royalties and, in some cases, co‑commercialization arrangements; a notable commercial success from such collaborations is daratumumab (marketed as DARZALEX by Janssen) for multiple myeloma. Genmab is publicly listed and focuses R&D investment on advancing its antibody platforms and clinical programs toward regulatory approval and commercial uptake.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

39.5%1Y

-25.0%3Y

-31.5%5Y

Performance

34.3%1Y

34.1%3Y

33.6%5Y

Volatility